ARK Genomic Revolution ETF (BATS:ARKG) Hits New 12-Month High – Should You Buy?

ARK Genomic Revolution ETF (BATS:ARKG) shares hit a new 52-week high on Tuesday . The stock traded as high as $49.96 and last traded at $49.85, with a volume of 1372721 shares trading hands. The stock had previously closed at $48.01.

ARK Genomic Revolution ETF Stock Up 4.9%

The company’s fifty day simple moving average is $41.10 and its 200-day simple moving average is $33.54.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Turner Financial Group Inc. purchased a new stake in ARK Genomic Revolution ETF in the second quarter valued at about $1,633,000. Continuum Advisory LLC purchased a new stake in shares of ARK Genomic Revolution ETF during the second quarter worth about $76,000. MBA Advisors LLC purchased a new stake in shares of ARK Genomic Revolution ETF during the second quarter worth about $270,000. SkyOak Wealth LLC acquired a new position in shares of ARK Genomic Revolution ETF during the second quarter valued at about $213,000. Finally, Beacon Financial Advisory LLC acquired a new position in shares of ARK Genomic Revolution ETF during the second quarter valued at about $245,000.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.